
Dec 9 (Reuters) - CVS Health (CVS) on Tuesday forecast 2026 profit above Wall Street estimates and this year's projected earnings, signalling steady progress in the health conglomerate's turnaround plan.
CVS stock rose 5% in early trading on Tuesday.
The company in October projected double-digit earnings growth for 2026 after raising its 2025 profit forecast for the third time.
"We are closing out 2025 with meaningful momentum across our businesses and we expect another year of strong earnings growth in 2026," said Chief Financial Officer Brian Newman on Tuesday.
The company forecast 2026 adjusted profit to be in the range of $7.00 to $7.20 per share, compared with analysts' average estimate of $7.16, according to data compiled by LSEG.
It, however, expects total revenue of at least $400 billion next year, below analysts' average estimate of $419.26 billion.
CVS also raised its 2025 adjusted profit forecast to $6.60 to $6.70 per share from $6.55 to $6.65 previously.
(Reporting by Sneha S K in Bengaluru; Editing by Shinjini Ganguli)
LATEST POSTS
- 1
Smooth countdown continues for Artemis II moon mission - 2
5 Home EV Chargers for Proficient and Solid Charging - 3
10 Hints for an Effective New employee screening - 4
Tehran synagogue damaged by missile strike according to Iranian media - 5
NAFFIC and Aware to Launch First China-Europe Digital Product Passport
What we know about Jonathan Ross, the ICE agent who shot and killed Renee Nicole Good in Minneapolis
Woman leaves bachelorette trip after trusting her gut about sketchy men partying it up with friends
5 Instructive Toy Brands for Youngsters
Tehran defends ship seizure as a legal action, but tensions continue in the Gulf
9 Under-The-Radar Malaysian Islands To Consider Instead Of Thailand Or Indonesia
New research reveals urban raccoons across the US show early signs of domestication
French high-speed train slams into truck, killing TGV driver
As world leaders enter climate talks, people in poverty have the most at stake
Bitcoin momentum builds in Abu Dhabi as global interest surges













